R. O'donnell

发表

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts.

G. Denardo, S. Denardo, L. Miers, 1998, Cancer biotherapy & radiopharmaceuticals.

Prospective evaluation of cancer clinical trial accrual patterns: identifying potential barriers to enrollment.

D. Gandara, P. Lara, F. Meyers, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Splenic volume change and nodal tumor response in non-Hodgkin's lymphoma patients after radioimmunotherapy using radiolabeled Lym-1 antibody.

Sui Shen, Christine Hartmann-Siantar, Aina Yuan, 2005, Cancer biotherapy & radiopharmaceuticals.

SPLENIC VOLUME CHANGE AND THERAPUETIC RESPONSE IN PATIENTS TREATED WITH RADIOMMUNOCONJUGATES

G. Denardo, S. Denardo, S. Shen, 2005 .

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial.

R. Ceriani, G. Denardo, S. Denardo, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.

G. Denardo, S. Denardo, S. Shen, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Strategies for developing effective radioimmunotherapy for solid tumors.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Novel mTORC1 Inhibitors Kill Glioblastoma Stem Cells

G. Cortopassi, K. Woolard, A. Tomilov, 2020, bioRxiv.

Early diagnosis and successful treatment of a patient with transfusion‐associated GVHD with autologous peripheral blood progenitor cell transplantation

P. Holland, R. O’Donnell, J. Tuscano, 2002, Transfusion.

Disulfide cross-linked micelles for the targeted delivery of vincristine to B-cell lymphoma.

K. Lam, K. Xiao, Juntao Luo, 2012, Molecular pharmaceutics.

The HB22.7 Anti-CD22 monoclonal antibody enhances bortezomib-mediated lymphomacidal activity in a sequence dependent manner

R. O’Donnell, H. McKnight, J. Tuscano, 2011, Journal of hematology & oncology.

The Bispecific Anti-CD20/CD22 Antibody (Bs20x22) Has More Lymphomacidal Activity Than the Parent Antibodies Both Alone or In Combination

J. Tuscano, L. Newell, Yunpeng Ma, 2010 .

Phase I Trial of High-Dose Tamoxifen in Combination with Cisplatin in Patients with Lung Cancer and Other Advanced Malignancies

E. Perez, D. Gandara, M. Edelman, 2003, Cancer investigation.

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

J. Tuscano, Loretta Sullivan-Chang, R. O'donnell, 2013, BioDrugs.

A phase I study of 90Y-2IT-BAD-Lym-1 in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Anticancer research.

67Copper-2-iminothiolane-6-[p-(bromoacetamido)benzyl-TETA-Lym-1 for radioimmunotherapy of non-Hodgkin's lymphoma.

K. Lamborn, G. Denardo, S. Denardo, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Efficacy of a CD22-targeted antibody-saporin conjugate in a xenograft model of precursor-B cell acute lymphoblastic leukemia.

N. Satake, R. O’Donnell, J. Tuscano, 2013, Leukemia research.

Efficacy and toxicity of a CD22-targeted antibody-saporin conjugate in a xenograft model of non-Hodgkin’s lymphoma

R. O’Donnell, J. Tuscano, J. Kato, 2012, Oncoimmunology.

CD22 antigen is broadly expressed on lung cancer cells and is a target for antibody-based therapy.

D. Gandara, R. O’Donnell, D. Pearson, 2012, Cancer research.

Efficacy, Biodistribution, and Pharmacokinetics of CD22-Targeted Pegylated Liposomal Doxorubicin in a B-cell Non–Hodgkin's Lymphoma Xenograft Mouse Model

J. Tuscano, W. Zamboni, Yunpeng Ma, 2010, Clinical Cancer Research.

Dose, timing, schedule, and the choice of targeted epitope alter the efficacy of anti-CD22 immunotherapy in mice bearing human lymphoma xenografts

R. O’Donnell, D. Pearson, H. McKnight, 2009, Cancer Immunology, Immunotherapy.

Development and characterization of CD22-targeted pegylated-liposomal doxorubicin (IL-PLD)

R. O’Donnell, J. Tuscano, W. Zamboni, 2009, Investigational New Drugs.

Anti-CD22 ligand-blocking antibody HB22.7 has independent lymphomacidal properties and augments the efficacy of 90Y-DOTA-peptide-Lym-1 in lymphoma xenografts.

K. Lamborn, G. Denardo, L. Miers, 2003, Blood.

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts.

K. Lamborn, G. Denardo, S. Denardo, 1997, Proceedings of the National Academy of Sciences of the United States of America.

Targeting CD22 in B-cell Malignancies: Current Status and Clinical Outlook

R. O’Donnell, J. Tuscano, Loretta Sullivan-Chang, 2013, BioDrugs.

The HB22.7–vcMMAE antibody–drug conjugate has efficacy against non-Hodgkin lymphoma mouse xenografts with minimal systemic toxicity

J. Tuscano, J. Kato, G. Barisone, 2016, Cancer Immunology, Immunotherapy.

Therapeutics , Targets , and Chemical Biology CD 22 Antigen IsBroadlyExpressedonLungCancerCells and Is a Target for Antibody-Based Therapy

D. Gandara, D. Pearson, J. Tuscano, 2012 .

Lenalidomide plus rituximab can produce durable clinical responses in patients with relapsed or refractory, indolent non‐Hodgkin lymphoma

J. Tuscano, J. Welborn, M. Abedi, 2014, British journal of haematology.

High-Dose Radioimmunotherapy Combined with Fixed, Low-Dose Paclitaxel in Metastatic Prostate and Breast Cancer by Using a MUC-1 Monoclonal Antibody, m170, Linked to Indium-111/Yttrium-90 via a Cathepsin Cleavable Linker with Cyclosporine to Prevent Human Anti-mouse Antibody

K. Lamborn, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates.

G. Denardo, S. Denardo, D. Kukis, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effect of antilymphoma antibody, 131I-Lym-1, on peripheral blood lymphocytes in patients with non-Hodgkin's lymphoma.

K. Lamborn, O. Schillaci, G. Denardo, 2007, Cancer biotherapy & radiopharmaceuticals.

Are radiometal-labeled antibodies better than iodine-131-labeled antibodies: comparative pharmacokinetics and dosimetry of copper-67-, iodine-131-, and yttrium-90-labeled Lym-1 antibody in patients with non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, S. Shen, 2000, Clinical lymphoma.

Peripheral blood stem cell mobilization for hematopoietic support of radioimmunotherapy in patients with breast carcinoma

G. Denardo, S. Denardo, R. O’Donnell, 1997, Cancer.

Treatment of refractory large granular lymphocytic leukemia with 2‐chlorodeoxyadenosine

M. Edelman, R. O’Donnell, Ivan Meadows, 1997, American journal of hematology.

Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium‐DOTA‐peptide‐ChL6

K. Lamborn, G. Denardo, S. Denardo, 2002, The Prostate.

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy.

K. Lamborn, G. Denardo, S. Denardo, 2000, Cancer biotherapy & radiopharmaceuticals.

Enhancement of the Therapeutic Index: From Nonmyeloablative and Myeloablative toward Pretargeted Radioimmunotherapy for Metastatic Prostate Cancer

J. Gregg, G. Denardo, S. Denardo, 2005, Clinical Cancer Research.

Enhancement of theTherapeutic Index : FromNonmyeloablative andMyeloablative toward Pretargeted Radioimmunotherapy forMetastatic Prostate Cancer

G. Denardo, S. Denardo, H. Albrecht, 2005 .

Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice.

K. Lam, K. Lamborn, G. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Characterization of canine neutrophil granules

B. Andersen, R. O’Donnell, R. O'donnell, 1982, Infection and immunity.

CD22-Binding Peptides Derived from Anti-CD22 Ligand Blocking Antibodies Retain the Targeting and Cell Killing Properties of the Parent Antibodies and May Serve as a Drug Delivery Vehicle

K. Lam, D. Pearson, H. McKnight, 2008, International Journal of Peptide Research and Therapeutics.

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma.

S Shen, G L DeNardo, K. Lamborn, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhanced therapeutic index of radioimmunotherapy (RIT) in prostate cancer patients: comparison of radiation dosimetry for 1,4,7,10-tetraazacyclododecane-N,N',N",N"'-tetraacetic acid (DOTA)-peptide versus 2IT-DOTA monoclonal antibody linkage for RIT.

K. Lamborn, G. Denardo, S. Denardo, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

Dosimetry-based therapy in metastatic breast cancer patients using 90Y monoclonal antibody 170H.82 with autologous stem cell support and cyclosporin A.

G. Denardo, S. Denardo, S. Shen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A revolution in the treatment of non-Hodgkin's lymphoma.

G. Denardo, S. Denardo, R. Oldham, 1998, Cancer biotherapy & radiopharmaceuticals.

Practical determination of organ S values for individual patients for therapy.

G. Denardo, S. Denardo, S. Shen, 1997, Nuclear medicine and biology.

Radioimmunotherapy for advanced breast cancer using I-131-ChL6 antibody.

K. Lamborn, G. Denardo, S. Denardo, 1997, Anticancer research.

Efficacy and toxicity of radioimmunotherapy with 90Y‐DOTA‐peptide‐ChL6 for PC3‐tumored mice

K. Lamborn, G. Denardo, S. Denardo, 2000, The Prostate.

A purified, fermented, extract of Triticum aestivum has lymphomacidal activity mediated via natural killer cell activation

J. Tuscano, Yunpeng Ma, G. Barisone, 2018, PloS one.

Concentration in Blood and Body Practical Determination of Patient-Specific Marrow Dose Using Radioactivity

G. Denardo, S. Denardo, S. Shen, 2006 .

Efficacy of Combined Histone Deacetylase and Checkpoint Kinase Inhibition in a Preclinical Model of Human Burkitt Lymphoma

R. O’Donnell, J. Tuscano, G. Barisone, 2015, Molecular medicine.

Histone deacetylase inhibition enhances the lymphomacidal activity of the anti-CD22 monoclonal antibody HB22.7.

R. O’Donnell, J. Tuscano, G. Barisone, 2014, Leukemia research.

Radioimmunotherapy of acquired immunodeficiency syndrome (AIDS) associated lymphoma.

G. Denardo, S. Shen, D. Kukis, 1999, Cancer biotherapy & radiopharmaceuticals.

Preclinical evaluation of chimeric L6 antibody for the treatment of Kaposi's sarcoma with radioimmunotherapy.

L. Howell, G. Denardo, S. Denardo, 1999, Cancer biotherapy & radiopharmaceuticals.

L6 monoclonal antibody binds prostate cancer

G. Denardo, S. Denardo, F. Meyers, 1998, The Prostate.

Importance of temporal relationships in combined modality radioimmunotherapy of breast carcinoma

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

High-affinity L-arabinose transport operon. Nucleotide sequence and analysis of gene products.

S. Miller, L. Polgár, B. Horazdovsky, 1987, Journal of molecular biology.

Imaging and Pharmacokinetics of 64Cu-DOTA-HB22.7 Administered by Intravenous, Intraperitoneal, or Subcutaneous Injection to Mice Bearing Non-Hodgkin’s Lymphoma Xenografts

C. Abbey, J. Sutcliffe, D. Kukis, 2009, Molecular Imaging and Biology.

Comparison of normal tissue pharmacokinetics with 111In/90Y monoclonal antibody m170 for breast and prostate cancer.

G. Denardo, S. Denardo, J. Lehmann, 2006, International journal of radiation oncology, biology, physics.

Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations.

S. Denardo, R. O’Donnell, Q. Salako, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Enhancement of 67Cu‐2IT‐BAT‐LYM‐1 therapy in mice with human burkitt's lymphoma (Raji) using interleukin‐2

K. Lamborn, G. Denardo, S. Denardo, 1997, Cancer.

Antibody responses to macrocycles in lymphoma.

G. Denardo, S. Denardo, C. Meares, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

The Bs20x22 anti-CD20-CD22 bispecific antibody has more lymphomacidal activity than do the parent antibodies alone

R. O’Donnell, J. Tuscano, J. Kato, 2011, Cancer Immunology, Immunotherapy.

Radioimmunotherapy with 111in/90y-2it-BAD-m170 for metastatic prostate cancer

G. Denardo, S. Denardo, S. Shen, 2001 .

Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials.

J. Buckner, E. Korn, G. Hortobagyi, 2013, Journal of the National Cancer Institute.

Canine neutrophil plasma membrane markers.

B. Andersen, R. O’Donnell, R. O'donnell, 1985, Biochimica et biophysica acta.

A phase I trial of escalating doses of cixutumumab (IMC-A12) and sorafenib in the treatment of advanced hepatocellular carcinoma

Y. Yen, D. Gandara, H. Lenz, 2018, Cancer Chemotherapy and Pharmacology.

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients.

G. Denardo, S. Denardo, S. Shen, 1999, Nuclear medicine and biology.

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer.

F. Meyers, G. Denardo, S. Denardo, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Imaging for improved prediction of myelotoxicity after radioimmunotherapy

G. Denardo, S. Denardo, S. Shen, 1997, Cancer.

Prediction of myelotoxicity using radiation doses to marrow from body, blood and marrow sources.

G. Denardo, S. Denardo, S. Shen, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Metabolite production in patients with lymphoma after radiometal-labeled antibody administration.

G. Denardo, S. Denardo, S. Shen, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A phase I trial of escalating doses of the anti-IGF-1R monoclonal antibody (mAb) cixutumumab (IMC-A12) and sorafenib for treatment of advanced hepatocellular carcinoma (HCC).

D. Gandara, H. Lenz, A. El-Khoueiry, 2010 .

Treatment of non-Hodgkin’s lymphoma xenografts with the HB22.7 anti-CD22 monoclonal antibody and phosphatase inhibitors improves efficacy

D. Pearson, H. McKnight, Y. Ma, 2009, Cancer Immunology, Immunotherapy.

Unravelling the immune contexture of pre-invasive lesions of the lung by multispectral imaging

J. Galon, Mihaela Angelova, C. Mascaux, 2018 .

An Evaluation of Barriers to Accrual in the Era of Legislation Requiring Insurance Coverage of Cancer Clinical Trial Costs in California

L. Beckett, D. Gandara, H. Chew, 2004, Cancer journal.

Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates.

G. Denardo, S. Denardo, R. O’Donnell, 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Exercise Renography in Untreated Subjects with Essential Hypertension

J. Sally, G. Denardo, R. O'donnell, 1996 .

Impact of interpatient pharmacokinetic variability on design considerations for therapy with radiolabeled MAbs.

G. Denardo, S. Denardo, S. Shen, 2003, Cancer biotherapy & radiopharmaceuticals.

Phosphatase inhibition augments anti-CD22-mediated signaling and cytotoxicity in non-hodgkin's lymphoma cells.

R. O’Donnell, D. Pearson, H. McKnight, 2009, Leukemia research.

Planning time for peripheral blood stem cell infusion after high-dose targeted radionuclide therapy using dosimetry.

G. Denardo, S. Denardo, S. Shen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Nuclear localizing sequences: an innovative way to improve targeted radiotherapy.

R. O’Donnell, R. O'donnell, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Milestones in the development of Lym-1 therapy.

G. Denardo, S. Denardo, G. Mirick, 1999, Hybridoma.

Maximum tolerated dose of 67Cu-2IT-BAT-LYM-1 for fractionated radioimmunotherapy of non-Hodgkin's lymphoma: a pilot study.

G. Denardo, S. Denardo, S. Shen, 1998, Anticancer research.

Prediction of myelotoxicity using semi-quantitative marrow image scores.

G. Denardo, S. Denardo, A. Yuan, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

A preliminary cell kinetics model of thrombocytopenia after radioimmunotherapy.

T. Jones, G. Denardo, S. Denardo, 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

R2: Preliminary Results of a Phase II Study of Lenalidomide and Rituximab in Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (NHL).

J. Tuscano, M. Dutia, K. Chee, 2008 .

Stability of monoclonal antibodies, Lym-1 and ChL6, and 2IT-BAD-Lym-1 immunoconjugate with ultra freezer storage.

G. Denardo, S. Denardo, S. Shen, 1999, Cancer biotherapy & radiopharmaceuticals.